8-K: Kyverna Therapeutics Reports Positive Miv-cel Data

Kyverna Therapeutics announced positive one-year data from its registrational trial for stiff person syndrome and longer-term follow-up data for generalized myasthenia gravis, reinforcing the potential of its miv-cel therapy.

Summary

• Kyverna Therapeutics announced positive one-year topline data from its registrational trial (KYSA-8) of miv-cel in patients with stiff person syndrome (SPS).
• The company also reported positive longer-term follow-up data from the Phase 2 portion of its registrational trial (KYSA-6) of miv-cel in patients with generalized myasthenia gravis (gMG).
• The data demonstrate durable clinical responses and a favorable safety profile for miv-cel, a CAR T-cell therapy.
• For SPS, 95% of patients who achieved a clinically meaningful improvement at the primary analysis sustained their benefit at 12 months, and over one-third completed the timed 25-Foot Walk in under 5 seconds.
• In gMG, clinically meaningful improvements were maintained for at least one year in five patients, with 57% achieving minimal symptom expression (MSE) as of their last follow-up.
• The rolling Biologics License Application (BLA) submission for miv-cel in SPS is on track for completion in Q4 2026.
• Phase 3 enrollment for the gMG trial is expected to be completed in mid-2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, with strong clinical data supporting a potentially groundbreaking therapy for underserved autoimmune diseases.

Positives

• Sustained clinical benefit and reversal of disability through one year in SPS patients, supporting miv-cel's potential as a first-in-class therapy.
• 95% of SPS patients who showed initial improvement maintained it at 12 months.
• Over one-third of SPS patients achieved a timed 25-Foot Walk time comparable to healthy adults.
• 67% of SPS patients who previously required a walking aid no longer need one.
• 92% of SPS patients remained free of chronic immunotherapies for SPS at 12 months.
• Robust and durable clinical responses in gMG patients sustained for up to 1.5 years.
• 57% of gMG patients maintained minimal symptom expression (MSE) as of last follow-up.
• 100% of gMG patients remained free of immunotherapies for MG at 24 weeks, with 86% remaining off immunosuppressants as of last follow-up.
• Consistent, well-tolerated safety profile with no high-grade CRS or ICANS observed in either trial.
• Rolling BLA submission for miv-cel in SPS is on track for completion in Q4 2026.

Negatives

• While data is positive, the Phase 3 enrollment for gMG is not expected to be completed until mid-2027, indicating a longer timeline for potential market entry for this indication.
• The filing does not provide specific numbers for the percentage of patients who achieved a 3-point improvement in MG-ADL in the Phase 3 gMG trial compared to SOC, only stating it as a secondary endpoint.

Risks

• The possibility that topline results may change following further analysis or differ from final results.
• Results from prior clinical trials may not necessarily be predictive of future results.
• Uncertainties related to market conditions.
• Risks related to the timing and outcome of regulatory submissions and interactions with the FDA.
• The ability to enroll patients in clinical trials on anticipated timelines.

Future Outlook

The rolling BLA submission for miv-cel in SPS is on track for completion in Q4 2026. Phase 3 enrollment for the gMG trial is expected to be completed in mid-2027. The company anticipates delivering one-time transformative therapies for patients with serious neurologic autoimmune conditions.

Management Comments

• "The durable clinical responses achieved in SPS and gMG, combined with a consistently favorable safety profile, set a new benchmark for autoimmune CAR T and reinforce miv-cels potential best-in-class profile and ability to transform the treatment landscape across neurologic autoimmune diseases," said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.
• "These one-year SPS data further strengthen our rolling BLA submission, which is on track to be completed in the fourth quarter of this year. Miv-cel's differentiated construct and well-established manufacturing process underpin these longer-term results and highlight the opportunity to deliver one-time transformative therapies for people living with serious neurologic autoimmune conditions."
• "The results from KYSA-8 are compelling, particularly given the severe burden of SPS and the absence of approved therapies. After a single dose of miv-cel, the sustained improvements observed in mobility, stiffness and other disease-specific measures, together with a well-tolerated profile, underscore its potential to deliver significant, long-lasting benefit to patients with SPS," said Amanda Piquet, M.D., FAAN, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine.
• "In SPS, we continue to see powerful evidence that a single dose of miv-cel has the potential to reset the immune system, reverse disease progression, and free patients from chronic immunotherapies, delivering sustained clinical benefit and a well-tolerated safety profile," said Naji Gehchan, M.D., Chief Medical and Development Officer of Kyverna Therapeutics.
• "Similarly, clinically meaningful responses were sustained to at least one year in our Phase 2 gMG trial, with nearly all patients remaining off immunosuppressant therapies. These unprecedented outcomes, combined with miv-cel's differentiated profile as a fully human CD19 CAR T-cell therapy with CD28 co-stimulation, distinguish miv-cel from both approved and investigational treatments, and strongly support our ongoing Phase 3 registrational trial. Most importantly, they bring us closer to our goal of delivering durable, drug-free, disease-free remission for patients living with neurologic autoimmune diseases."

Industry Context

StockSavvy.ai notes that these results position Kyverna Therapeutics at the forefront of CAR T-cell therapy for autoimmune diseases, a rapidly evolving field. The positive data in both Stiff Person Syndrome and Generalized Myasthenia Gravis, particularly the durability and safety profile, could set a new standard of care and differentiate miv-cel from other investigational therapies.

Stakeholder Impact

• Shareholders: Positive data and progress towards BLA submission are likely to be viewed favorably, potentially impacting stock price.
• Patients with SPS and gMG: The data suggest a potential for a transformative, single-dose therapy that could offer durable remission and freedom from chronic treatments.
• Healthcare Providers: The results may influence treatment decisions and highlight miv-cel as a significant advancement in autoimmune disease therapy.
• Regulatory Authorities (FDA): The positive data will be crucial for the ongoing review of the BLA submission.

Next Steps

• Complete rolling BLA submission for miv-cel in SPS in Q4 2026.
• Present full data set from KYSA-8 at MS Toronto (ACTRIMS-ECTRIMS meeting) October 21-23, 2026.
• Present longer-term follow-up data from KYSA-6 at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting on September 29, 2026.
• Complete Phase 3 enrollment for the KYSA-6 trial in gMG by mid-2027.

Key Dates

Recommendation

The clinical data presented is highly encouraging, demonstrating significant efficacy and a favorable safety profile for miv-cel in two serious autoimmune diseases. The progress towards a BLA submission for SPS is a key de-risking event. However, the Phase 3 trial for gMG is still in enrollment, and regulatory approval timelines are not guaranteed. While the outlook is positive, a 'hold' recommendation allows for further observation of regulatory outcomes and Phase 3 trial progress before considering a more aggressive stance.

Keywords

miv-cel, Kyverna Therapeutics, Stiff Person Syndrome, Generalized Myasthenia Gravis, CAR T-cell therapy, autoimmune disease, clinical trial data, BLA submission